Search Results
Oct 24, 2025, 12:14 ET Procedimentos estéticos injetáveis: quando é o momento certo para começar?
Dermatol Surg. 2016 Jun;42(6):699-709 2. Di Gregorio C et al. Clin Cosmet Investig Dermatol. 2022 Apr 14;15:681-690. 3. Talarico S et al. Dermatol Surg.
More news about: Galderma
Oct 22, 2025, 08:07 ET CND Life Sciences Announces NIH Grant to Study the Risk of Parkinson's Disease in Patients with Essential Tremor
10.1002/mds.22161.3 Louis ED, Berry D, Ghanem A, et al. Conversion Rate of Essential Tremor to Essential Tremor Parkinson Disease. Neurology Clin Practice, 2023;13(3).
More news about: CND Life Sciences
Oct 22, 2025, 08:00 ET Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019;104:5893-5905.
More news about: Astellas Pharma Inc.
Oct 21, 2025, 19:30 ET PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
. 5 Funt SA, Rosenberg JE. Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol. 2017 Apr;14(4):221-234. doi: 10.1038/nrclinonc.2016.188. Epub 2016 Nov 22. PMID: 27874062; PMCID: PMC6054138.6 Esteban-Villarrubia
More news about: Astellas Pharma Inc.
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
S, Lee-Smith W, Altorok N. Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis. Clin Rheumatol. 2022 Dec;41(12):3615-3627. Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, Greenberg JD. Greater
More news about: AbbVie
Oct 17, 2025, 16:00 ET FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
al. Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2016; 4 (4): 565-572. Bachert C, et al. Phenotypes and Emerging Endotypes of Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2016; 4 (4): 621-628.
More news about: Amgen
Oct 17, 2025, 10:00 ET Boehringer's HERNEXEOS® demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
M. E. et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin. cancer Res. an Off. J. Am. Assoc. Cancer Res. 18, 4910–4918 (2012). Galogre M, et al. A review of HER2 overexpression and
More news about: Boehringer Ingelheim
Oct 17, 2025, 08:00 ET Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE) [published online ahead of print, September 20, 2020]. J Clin Oncol. doi:10.1200/JCO.20.02514. Verzenio [package insert]. Indianapolis, IN: Eli Lilly and Company.
More news about: Eli Lilly and Company
Oct 16, 2025, 14:31 ET De l'amorçage à l'expansion : les nouvelles voies de croissance tracées à Paris par Xiaohongshu et WWD
créatrice, est allée droit au but : « Rester vrai, rester optimiste et ne jamais trahir son propre code, car les abonnés découvriront la vérité en un clin d'œil. » Comme l'explique Martin Barthel, associé et directeur général du Boston Consulting Group, « la génération Z est en passe
More news about: WWD
Oct 16, 2025, 14:29 ET Breakthrough or Band-Aid? New Drug for Primary Aldosteronism Sparks Debate
and Diagnosis. Adrenal.com. Adler GK et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2025 Aug 7;110(9):2453-2495. doi: 10.1210/clinem/dgaf284.
More news about: Carling Adrenal Center
Oct 16, 2025, 10:30 ET Anvisa aprova nova indicação para durvalumabe da AstraZeneca que reduz em 32% o risco de recidiva no câncer de pulmão operável[1]
Antonia SJ, et al. N Engl J Med. 2017;377(20):1919–29.[10] Paz-Ares L, et al. Lancet. 2019;394(10212):1929-39.[11] Finn RS, et al. J Clin Oncol. 2023;41(3):556-566. BR- 43516. Material destinado à imprensa. Aprovado em
More news about: AstraZeneca
Oct 14, 2025, 20:00 ET Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019;104:5893-5905. 4 Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b,
More news about: Astellas Pharma Inc.
Oct 14, 2025, 09:05 ET Prolacta Bioscience Approaches 20 Years Nourishing Extremely Premature Babies as #1 Hospital Provider of Human Milk-Based Fortifiers and Formulas
weighing <1250 g: a randomized clinical trial [published correction appears in Am J Clin Nutr. 2019 Aug 1;110(2):529] [published correction appears in Am J Clin Nutr. 2020 May 1;111(5):1112]. Am J Clin Nutr. 2018;108(1):108-116. doi:10.1093/ajcn/nqy067 Ganapathy V,
More news about: Prolacta Bioscience
Oct 14, 2025, 09:00 ET O Positiv Expands at Target with Two New Women's Health Essentials
7/1/25 Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab Care. 2004 Jul;7(4):405-10. doi: 10.1097/01.mco.0000134362.76653.b2. PMID: 15192443; PMCID: PMC2804956.
More news about: O Positiv Health
Oct 13, 2025, 10:17 ET Boehringer and Click Therapeutics present pivotal data for investigational prescription digital therapeutic CT-155 showing a statistically significant reduction in negative symptoms of schizophrenia
Res. 2018;192:148-153. Kadakia A, Catillon M, Fan Q, et al. The economic burden of schizophrenia in the United States. J Clin Psychiatry. 2022 Oct 10;83(6):22m14458. Vaccaro J, Nili M, Xiang P, et al. Economic burden associated with negative symptoms
More news about: Boehringer Ingelheim Pharmaceuticals, Inc.; Click Therapeutics
Oct 13, 2025, 07:15 ET AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
Recent Advances and Future Challenges in Pancreatic Cancer Care: Early Detection, Liquid Biopsies, Precision Medicine and Artificial Intelligence. J Clin Med. 2023; 12(23):7485. doi:10.3390/jcm12237485 Cereda V and D'Andrea MR. Pancreatic cancer: failures and hopes—a review
More news about: AbbVie
Oct 10, 2025, 07:30 ET Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
depressive disorder on comorbidities: a systematic literature review. J Clin Psychiatry. 2022;83(6):21r14328. Nutt D, Wilson S, Paterson L. Sleep disorders are core symptoms of depression. Dialogues Clin Neurosci. 2008 Sep; 10(3): 329–336. Taddei-Allen
More news about: Johnson & Johnson
Oct 09, 2025, 08:22 ET Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
Jemal A, Bray F. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024;74(3):229-263.
More news about: Henlius
Oct 09, 2025, 07:38 ET 開創無化療時代：全球首個H藥胃癌圍手術期III期臨床研究達到主要終點，支持提前申報上市
Jemal A, Bray F. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024;74(3):229-263.
More news about: 復宏漢霖
Oct 09, 2025, 00:39 ET 艾曲莫德亞洲多中心Ⅲ期臨床ENLIGHT UC研究（ES101002）結果榮登《柳葉刀》子刊《The Lancet Gastroenterology & Hepatology》
[1] 2024年《期刊引證報告》（Clarivate 2025）中為38.6，CiteScore指數值為51.1。[2] 岑俊威,等.中外醫學研究,2021,19(16):182-184.[3] Fumery M, et al. Clin Gastroenterol Hepatol. 2018 Mar;16(3):343-356.e3[4] Eaden JA, Abrams KR, Mayberry JF. Gut. 2001;48(4):526-535. doi:10.1136/gut.48.4.526[5]
More news about: 雲頂新耀
Oct 08, 2025, 19:42 ET Le Master Puff de Bosideng : Une grande marque chinoise fait ses débuts à Paris
fonction à la liberté. La silhouette en forme de O, qui fait écho à la forme du Puff et du dôme en forme de pomme de pin, symbolise un retour à zéro - un clin d'œil aux 49 années de réinvention constante de Bosideng.
More news about: Bosideng
Oct 08, 2025, 14:02 ET Synchrony Medical Launches LibAirty™ Airway Clearance System in the U.S., Offering a New Standard for At-Home Respiratory Care
Helper N, Ashkenazi M, Sokol G, Dagan A, Efrati O. A Novel Medical Device for Airway Clearance. J Clin Med. 2025 Jan 30;14(3):907.Mingora C, Barfield W, Shani A, Tzfoni T, Flume P. Evaluation of the Safety and Efficacy of LibAirty™ Airway
More news about: Synchrony Medical
Oct 08, 2025, 10:00 ET Clin Ops Solutions Launches Clinical Research Steering Committee to Advance Excellence in Clinical Trials
Clin Ops Solutions, a leader in clinical research consulting and recruitment services, today announced the formation of its
More news about: Clin Ops Solutions
Oct 07, 2025, 13:22 ET CND Life Sciences is Granted FDA Breakthrough Device Designation for Its Skin Biopsy-Based Syn-One Test®
Tinaz, S., Santini, V. and Zubair, A. (2025), Utilization of Skin Punch Biopsy for the Diagnosis of α-Synucleinopathy in Clinical Practice. Mov Disord Clin Pract. doi.org/10.1002/mdc3.70272
More news about: CND Life Sciences
Oct 07, 2025, 09:00 ET ZEISS expands DORC portfolio and further strengthens digital footprint with improved workflow efficiency and digital visualization
7Skalicky, S.E., Martin, K.R., Fenwick, E., Crowston, J.G., Goldberg, I. and McCluskey, P. (2015), Cataract and quality of life in glaucoma. Clin Experiment Ophthalmol, 43: 335-341.
More news about: Carl Zeiss Meditec AG